Market closed
AbbVie/$ABBV
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Ticker
$ABBV
Sector
Trading on
NYSE
Industry
Biotechnology
Headquarters
Employees
50,000
Website
AbbVie Metrics
BasicAdvanced
$308B
Market cap
60.78
P/E ratio
$2.87
EPS
0.61
Beta
$6.13
Dividend rate
3.76%
Dividend yield
Price and volume
Market cap
$308B
Beta
0.61
52-week high
$202.32
52-week low
$136.30
Average daily volume
5.5M
Dividend rate
$6.13
Financial strength
Current ratio
0.645
Quick ratio
0.436
Long term debt to equity
967.765
Total debt to equity
1,039.994
Dividend payout ratio (TTM)
212.79%
Interest coverage (TTM)
6.47%
Management effectiveness
Return on assets (TTM)
7.72%
Return on equity (TTM)
56.41%
Valuation
Price to earnings (TTM)
60.779
Price to revenue (TTM)
5.556
Price to book
51.1
Price to tangible book (TTM)
-3.21
Price to free cash flow (TTM)
19.748
Dividend yield (TTM)
3.51%
Forward dividend yield
3.76%
Growth
Revenue change (TTM)
0.72%
Earnings per share change (TTM)
-21.44%
3-year revenue growth (CAGR)
0.22%
3-year earnings per share growth (CAGR)
-11.89%
3-year dividend per share growth (CAGR)
6.04%
What the Analysts think about AbbVie
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for AbbVie stock.
AbbVie Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AbbVie Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AbbVie News
AllArticlesVideos
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
Benzinga·14 hours ago
AbbVie's loss is Bristol Myers Squibb's gain - analyst
Proactive Investors·17 hours ago
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
Market Watch·19 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market closed
Upcoming events
Nov
15
AbbVie
Dividend·Payment
$1.55
Per share
Jan
15
AbbVie
Dividend·Ex-dividend
Feb
14
AbbVie
Dividend·Payment
$1.64
Per share
FAQs
What’s the current market cap for AbbVie stock?
AbbVie (ABBV) has a market cap of $308B as of November 13, 2024.
What is the P/E ratio for AbbVie stock?
The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 60.78 as of November 13, 2024.
Does AbbVie stock pay dividends?
Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of November 13, 2024, the dividend rate is $6.13 and the yield is 3.76%. AbbVie has a payout ratio of 212.79% on a trailing twelve-month basis.
When is the next AbbVie dividend payment date?
The next AbbVie (ABBV) dividend payment is scheduled for November 15, 2024.
What is the beta indicator for AbbVie?
AbbVie (ABBV) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.